Search
Busulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalBusulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. … According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDichlorobenzyl alcohol
go.drugbank.com/drugs/DB13269Approved[L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773] … [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalCFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. … Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class.
Cethromycin
go.drugbank.com/drugs/DB06419InvestigationalCethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system. … [A203369] Since this time, cethromycin has received FDA orphan drug designations for the prophylactic treatment of anthrax inhalation, plague due to _Yersinia pestis_, and tularemia due to _Francisella
Ambenonium
go.drugbank.com/drugs/DB01122ApprovedWithdrawnAmbenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigational[A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. … Hepatitis D is considered the most severe type of viral hepatitis and leads to the rapid development of cirrhosis, severe decompensation of liver function, and an increased risk of mortality.
Baricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigationalthe use of baricitinib for the treatment of COVID-19 in May 2022. … Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways.
Categories: MATE 2 Substrates with a Narrow Therapeutic Index, OAT3/SLC22A8 Substrates with a Narrow Therapeutic IndexGolodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigational[L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of … [A188580,T756] A similar drug used in the treatment of other types of DMD is [eteplirsen], which targets a different genetic mutation.
Categories: Compounds used in a research, industrial, or household settingPolihexanide
go.drugbank.com/drugs/DB12277ApprovedInvestigational[A1351] It is effective against a wide range of Gram-positive and Gram-negative bacteria. … [A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite.
Categories: Compounds used in a research, industrial, or household settingGefapixant
go.drugbank.com/drugs/DB15097Approved[L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.
Categories: combinations of sulfonamides